THYROCARENSEThyrocare Technologies LimitedMediumNeutral
Announced Thu, 7 May · 19:57 IST

Thyrocare Technologies Limited has informed the Exchange regarding Appointment of Mr. Uday Patel Kadam and Mr. Gaurav Verma as Non- Executive Director of the company w.e.f. May 08, 2026.

Multiple Ind Directors ResignedPromoter Family Board EntryManagement Changes View source PDF

THYROCARE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+1.3%1-day move
₹472.50
prior close
₹493.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+4.2+5.4+5.2+3.0+1.3-0.1+1.2-0.5-2.4-0.7+10.1+14.2+10.9
Up moveDown movePending
AI summary

Thyrocare Technologies held a Board meeting on May 7, 2026, approving several key matters. Two new Non-Executive, Non-Independent Directors were appointed: Mr. Uday Patel Kadam and Mr. Gaurav Verma (both effective May 8, 2026), both currently associated with API Holdings Limited. Simultaneously, two directors resigned - Mr. Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah - citing pre-occupation and other commitments. The Board recommended a final dividend of Rs. 7 per share for FY 2025-26, taking total dividend to Rs. 9.33 per share (post bonus adjustment). It also approved appointment of Price Waterhouse Chartered Accountants LLP as new statutory auditors, re-appointed CEO Mr. Rahul Franklin Guha for 5 years, approved up to Rs. 5.50 crore investment in subsidiary Think Health Diagnostics, and proposed amendments to the Memorandum of Association to expand healthcare business scope.

Likely market impact

The resignation of two directors and appointment of two new directors linked to API Holdings indicates board restructuring. The dividend declaration and expansion of business objects signal positive sentiment. However, director changes may raise questions about governance continuity.